WuXi XDC Reports Impressive Growth in First Half of 2026, Strengthens Dominance in CRDMO Sector

WuXi XDC's Strong Half-Year Performance in 2026

WuXi XDC Cayman Inc., under the stock code 2268.HK, has made waves in the bioconjugate sector, posting remarkable financial results for the first half of 2026. The company achieved a total revenue of RMB 3,701.4 million, marking a significant growth of 37.0% on an actual exchange rate (AER) basis, and an impressive 41.5% growth on a constant exchange rate (CER) basis. This achievement highlights the increasing momentum in the global demand for integrated bioconjugate contract research, development, and manufacturing organization (CRDMO) services.

Financial Highlights

The gross profit for the reporting period soared by 40.6% period-over-period, reaching RMB 1,371.3 million. This resulted in a gross profit margin of 37.0%, reflecting a 0.9 percentage point increase compared to the same period in 2025. Such improvements are attributed mainly to enhanced operational efficiencies and sustained customer demand.

Furthermore, the adjusted net profit attributable to the owners of the Company surged by 37.4% to RMB 1,027.3 million. The margin for this adjusted profit remained stable at 27.8%, showcasing the solidity of the Group's core business operations.

Customer Base Expansion

In a demonstration of its growing influence, WuXi XDC expanded its customer base to over 810 companies, with 15 of the top 20 global pharmaceutical firms partnering with them. This strategic expansion of clientele is linked to the company’s successful adoption of its